Despite Challenges, Congestive Heart Failure Draws A Crowd
This article was originally published in The Pink Sheet Daily
Biopharma companies are drawn to CHF, despite the lack of effective biomarkers and the need for large, expensive trials.
You may also be interested in...
Following the acquisition of Schering-Plough, Merck has one of the most robust pipelines in the industry, but after an R&D day May 11, much of the most interesting data is still yet to be seen.
Relaxin enables the pharma to expand its reach in acute cardiology as its mega-drug Diovan faces patent expiries.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.